201. Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study
- Author
-
Fang Guo, Xiangbo Kong, Xishuang Song, Tao Han, Changfu Li, Qifu Zhang, Zhendong Zheng, Chengge Li, Zhenhua Li, Shuxian Qu, Ying Piao, Yaling Han, Xiaodong Xie, and Zhaozhe Liu
- Subjects
Oncology ,Sorafenib ,medicine.medical_specialty ,medicine.medical_treatment ,Subgroup analysis ,renal cell cancer ,OncoTargets and Therapy ,Targeted therapy ,Metastasis ,Internal medicine ,medicine ,Pharmacology (medical) ,neoplasms ,Survival analysis ,Original Research ,Univariate analysis ,business.industry ,Cancer ,Retrospective cohort study ,targeted therapy ,medicine.disease ,Surgery ,sorafenib ,prognosis ,business ,medicine.drug - Abstract
Fang Guo,1,* Tao Han,1,* Zhaozhe Liu,1,* Xishuang Song,2 Qifu Zhang,3 Xiangbo Kong,4 Changfu Li,5 Zhenhua Li,6 Chengge Li,7 Shuxian Qu,1 Zhendong Zheng,1 Ying Piao,1 Yaling Han,8 Xiaodong Xie1 1Department of Oncology, Cancer Center of People’s Liberation Army, General Hospital of Shenyang Military Region, Shenyang City, 2Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, 3Department of Urology, Jilin Oncology Hospital, 4Department of Urology, China-Japan Union Hospital of Jilin University, Jilin City, Jilin Province, 5Department of Urology, Heilongjiang Oncology Hospital, Heilongjiang City, Heilongjiang Province, 6Department of Urology, First Affiliated Hospital of China Medical University, 7Department of Health Statistics, Shenyang Medical College, 8Department of Cardiology, Institute of Cardiovascular Research of People’s Liberation Army, General Hospital of Shenyang Military Region, Shenyang City, Liaoning Province, People’s Republic of China *These authors contributed equally to this work Abstract: The effects of sorafenib for Chinese patients with metastatic renal cell cancer (mRCC) were evaluated to figure out the relationship between clinical variables and prognosis. The data were analyzed retrospectively from six comprehensive cancer centers in Northeast China. All cases were diagnosed as mRCC histopathologically without exception. Patients were taken 400 mg sorafenib orally twice daily until progression of disease or intolerable toxic reaction occurred. Overall survival (OS), progression-free survival (PFS), and the influence of clinical variables on survival were appointed as main outcome measures. Clinical data were analyzed using SPSS statistical software. P
- Published
- 2015
- Full Text
- View/download PDF